PMID- 27913989
OWN - NLM
STAT- MEDLINE
DCOM- 20170905
LR  - 20210109
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 34
IP  - 1
DP  - 2017 Jan
TI  - Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line 
      Treatment for Invasive Aspergillosis.
PG  - 207-220
LID - 10.1007/s12325-016-0443-1 [doi]
AB  - INTRODUCTION: Invasive aspergillosis (IA) is associated with a significant 
      clinical and economic burden. The phase III SECURE trial demonstrated 
      non-inferiority in clinical efficacy between isavuconazole and voriconazole. No 
      studies have evaluated the cost-effectiveness of isavuconazole compared to 
      voriconazole. The objective of this study was to evaluate the costs and 
      cost-effectiveness of isavuconazole vs. voriconazole for the first-line treatment 
      of IA from the US hospital perspective. METHODS: An economic model was developed 
      to assess the costs and cost-effectiveness of isavuconazole vs. voriconazole in 
      hospitalized patients with IA. The time horizon was the duration of 
      hospitalization. Length of stay for the initial admission, incidence of 
      readmission, clinical response, overall survival rates, and experience of adverse 
      events (AEs) came from the SECURE trial. Unit costs were from the literature. 
      Total costs per patient were estimated, composed of drug costs, costs of AEs, and 
      costs of hospitalizations. Incremental costs per death avoided and per additional 
      clinical responders were reported. Deterministic and probabilistic sensitivity 
      analyses (DSA and PSA) were conducted. RESULTS: Base case analysis showed that 
      isavuconazole was associated with a $7418 lower total cost per patient than 
      voriconazole. In both incremental costs per death avoided and incremental costs 
      per additional clinical responder, isavuconazole dominated voriconazole. Results 
      were robust in sensitivity analysis. Isavuconazole was cost saving and dominant 
      vs. voriconazole in most DSA. In PSA, isavuconazole was cost saving in 80.2% of 
      the simulations and cost-effective in 82.0% of the simulations at the $50,000 
      willingness to pay threshold per additional outcome. CONCLUSION: Isavuconazole is 
      a cost-effective option for the treatment of IA among hospitalized patients. 
      FUNDING: Astellas Pharma Global Development, Inc.
FAU - Harrington, Rachel
AU  - Harrington R
AD  - Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA. 
      Rachel.Harrington@astellas.com.
FAU - Lee, Edward
AU  - Lee E
AD  - Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA.
FAU - Yang, Hongbo
AU  - Yang H
AD  - Analysis Group, Inc., 111 Huntington Ave, 14th Floor, Boston, MA, 02199, USA.
FAU - Wei, Jin
AU  - Wei J
AD  - Analysis Group, Inc., 111 Huntington Ave, 14th Floor, Boston, MA, 02199, USA.
FAU - Messali, Andrew
AU  - Messali A
AD  - Analysis Group, Inc., 111 Huntington Ave, 14th Floor, Boston, MA, 02199, USA.
FAU - Azie, Nkechi
AU  - Azie N
AD  - Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA.
FAU - Wu, Eric Q
AU  - Wu EQ
AD  - Analysis Group, Inc., 111 Huntington Ave, 14th Floor, Boston, MA, 02199, USA.
FAU - Spalding, James
AU  - Spalding J
AD  - Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161202
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Antifungal Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyridines)
RN  - 0 (Triazoles)
RN  - 60UTO373KE (isavuconazole)
RN  - JFU09I87TR (Voriconazole)
MH  - Antifungal Agents/*economics/therapeutic use
MH  - Aspergillosis/*drug therapy/mortality
MH  - Cost-Benefit Analysis
MH  - Fees, Pharmaceutical
MH  - Female
MH  - Hospitalization/economics
MH  - Humans
MH  - Male
MH  - Models, Econometric
MH  - Nitriles/*economics/therapeutic use
MH  - Pyridines/*economics/therapeutic use
MH  - Triazoles/*economics/therapeutic use
MH  - Voriconazole/*economics/therapeutic use
PMC - PMC5216061
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Infectious diseases
OT  - Invasive aspergillosis
OT  - Isavuconazole
OT  - Phase III trial
OT  - Sensitivity analyses
OT  - Voriconazole
EDAT- 2016/12/04 06:00
MHDA- 2017/09/07 06:00
PMCR- 2016/12/02
CRDT- 2016/12/04 06:00
PHST- 2016/08/23 00:00 [received]
PHST- 2016/12/04 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2016/12/04 06:00 [entrez]
PHST- 2016/12/02 00:00 [pmc-release]
AID - 10.1007/s12325-016-0443-1 [pii]
AID - 443 [pii]
AID - 10.1007/s12325-016-0443-1 [doi]
PST - ppublish
SO  - Adv Ther. 2017 Jan;34(1):207-220. doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 
      2.